Baxter partners with VIPUN Medical for gastric monitoring system

27 July 2020 (Last Updated July 27th, 2020 10:34)

Clinical nutrition company Baxter International has partnered with VIPUN Medical to commercialise the VIPUN Gastric Monitoring System.

Baxter partners with VIPUN Medical for gastric monitoring system
VIPUN Gastric Monitoring System helps clinicians make informed and faster nutrition therapy decisions in the ICU and other settings. Credit: Chokniti Khongchum / Pixabay.

Clinical nutrition company Baxter International has partnered with VIPUN Medical to commercialise the VIPUN Gastric Monitoring System.

As part of the agreement, Baxter will support the latter’s clinical studies required to achieve regulatory approval for the system in key markets and gain global distribution rights.

Additional terms of the agreement have not been disclosed.

VIPUN Gastric Monitoring System is designed to help clinicians make informed and faster nutrition therapy decisions in the intensive care unit (ICU) and other settings.

The system features a ‘smart’ enteral feeding tube to measure stomach motility to help clinicians identify enteral feeding intolerance and reduce the risks of malnutrition and feeding-related complications.

Baxter Clinical Nutrition business general manager Jorge Vasseur: “The VIPUN Gastric Monitoring System will be an important addition to Baxter’s nutrition portfolio.

“While indirect calorimetry can help determine individual energy requirements, the VIPUN Gastric Monitoring System is designed to help address the need for accurate, real-time detection of tolerance to enteral feeding. For patients intolerant to enteral nutrition, our broad portfolio of parenteral nutrition products is available to help ensure they get the nutrients they need.”

Enteral feeding intolerance (EFI) is a serious problem among patients in the ICU. Approximately four in ten patients in the ICU are affected by EFI, which often leads to malnutrition risk.

Parenteral nutrition may be the treatment modality used to reach nutrition targets when patients cannot tolerate enteral nutrition.

VIPUN Medical CEO Nico Van Tichelen said: “This innovative technology has the potential to significantly change the way clinicians provide nutrition therapy and directly enhance the care of the most vulnerable patients.

“In Baxter, we have found a partner who shares our commitment to helping to improve the practice of medical nutrition, as well as the resources and expertise to make this technology available to clinicians and patients who need it most.”

The VIPUN Gastric Monitoring System is an investigational device and is currently not available for sale.